FDA Approves Xarelto to Treat Blood Clots in Pediatric Patients

The FDA has approved Xarelto as tablets and oral suspension to treat blood clots in pediatric patients.

• The approval is for pediatric patients from birth to younger than 18 years who have received at least 5 days of injectable or intravenous treatment for blood clots
  • FDA has also approved Xarelto to prevent blood clots in pediatric patients two years and older with congenital heart disease after the Fontan procedure, a type of open-heart surgery
• FDA approved Xarelto in tablet form in 2011; Xarelto as an oral suspension is a new dosage form the agency approved today

To view the source ...